Analyst David Moskowitz joins Unigene as CFO
This article was originally published in Scrip
Peptide-based therapeutics developer Unigene Laboratories has appointed David Moskowitz to the newly created position of CFO. He joins the company after 13 years as a research analyst covering large-cap pharmaceutical and speciality pharmaceutical, biotechnology, and generic drug companies. He most recently served as senior pharmaceutical analyst for Roth Capital Partners where he developed research coverage of emerging speciality pharma and biotech companies.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.